Announcements Trials
Browse Landscape

Phase

Phase 2 44Phase 1 27Phase NA 15Phase 1/2 13Phase EARLY_PHASE1 2Phase 3 2Phase 2/3 2Phase 4 1

Status

Unknown 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Gene Expression Profiling × Clear all
NCT01099423 2017-02-08

SURTIME

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Unknown
99 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00553124 2014-01-10

Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
3,400 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡